William Barbo compensation by year
CHARLES RIVER LABORATORIES INTERNATIONAL Summary Compensation Table · all 8 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|
| Salary | $384,512 | $447,746 | $461,509 | $479,364 | $515,126 | $527,176 | $545,738 | $568,144 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $719,781 | $1,010,955 | $1,247,987 | $1,506,677 | $1,289,517 | $1,373,282 | $1,467,715 | $1,522,274 |
| Option awards | $181,382 | $255,214 | $318,015 | $375,155 | $325,281 | $339,892 | $365,944 | $382,395 |
| Non-equity incentive | $305,945 | $382,334 | $459,650 | $353,293 | $384,501 | $503,947 | $278,303 | $329,977 |
| Pension and deferred compensation | $37,750 | $60,068 | $0 | $151,099 | $0 | $0 | $0 | $0 |
| All other | $69,654 | $94,111 | $89,229 | $96,607 | $95,050 | $101,922 | $104,508 | $105,945 |
| Total | $1,699,024 | $2,250,428 | $2,576,389 | $2,962,196 | $2,609,475 | $2,846,219 | $2,762,209 | $2,908,735 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CHARLES RIVER LABORATORIES INTERNATIONAL, INC. DEF 14A filed March 29, 2024, accession 0001104659-24-040854, and prior-year filings. Open the filing on EDGAR.
How this page was built: the CHARLES RIVER LABORATORIES INTERNATIONAL, INC. filed document, accession 0001104659-24-040854. Every figure is read from that document and cited to the page and table it appears in. Filed March 29, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 16,417 | $3,880,979 | — |
| RSU | 4,035 | $953,874 | — |
| Option | 4,696 | — | $194.12 |
| Option | 1,514 | — | $179.66 |
| Option | 3,027 | — | $244.41 |
| Option | 1,555 | — | $337.99 |
Per the Outstanding Equity Awards at Fiscal Year-End table in CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
CHARLES RIVER LABORATORIES INTERNATIONAL’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| James Foster | Chair, President, Chief Executive Officer and Director | $14,096,924 |
| Birgit Girshick | Corporate Executive Vice President, Chief Operating Officer | $4,989,672 |
| Flavia Pease | Corporate Executive Vice President and Chief Financial Officer | $3,811,326 |
| Joseph LaPlume | Corporate Executive Vice President, Corporate Development & Strategy | $3,058,456 |
| William Barbo · this page | Corporate Executive Vice President | $2,908,735 |
The full CHARLES RIVER LABORATORIES INTERNATIONAL compensation record
free company briefThis page is one person within CHARLES RIVER LABORATORIES INTERNATIONAL's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the CHARLES RIVER LABORATORIES INTERNATIONAL proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CHARLES RIVER LABORATORIES INTERNATIONAL's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.